Navigation Links
Genentech and Novartis Remain Image Leaders in Oncology and Hematology
Date:6/2/2011

li>
  • Carefully read literature from the company
  • Enroll patients in company clinical trials

  • Amgen had its best year across all oncology stakeholders and jumped from fifth to third place in overall image among office-based and hospital-based oncologists. It also saw large gains in the Sales Force dimension, highlighting the impact a comprehensive approach to an office can make.

    Among hematologists, it's important to note that Celgene and Millennium: The Takeda Oncology Company captured two of the top five spots, challenging the perception that small companies cannot be image leaders.

    "Companies are realizing that image and reputation go beyond having the most products; it's about having knowledgeable, responsive sales reps that provide the objective data oncologists want and having the support programs and information nurses and practice managers need," said Dr. Shawn Wade, vice president and head of Specialty Pharmaceuticals at Market Strategies.

    For more information on this and other syndicated studies on European Oncologists/ Hematologists and top performers at ASCO, contact Brock Walter at 909.267.5443 or brock.walter@marketstrategies.com.

    About the StudyMarket Strategies' 2011 MSImage Oncology and Hematology Stakeholder Study was fielded via the Internet in February and March among 465 physicians, 100 oncology practice managers and 100 oncology nurses. To qualify, physicians and nurses were required to have a minimum number of oncology patients, spend at least 50 percent of their time in patient care and have exposure to sales representatives. To qualify as a practice manager, respondents were required to work in a practice with at least three oncologists and be responsible for billing and reimbursement. Respondents were recruited from a national e-research panel. Due to its opt-in nature, this online panel (like most others) does not yield a random probab
    '/>"/>

    SOURCE Market Strategies International
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
    2. Roche Intends to Commence Tender Offer to Acquire All Shares of Genentech for US$ 86.50 Per Share in Cash
    3. Roche and Genentech Reach a Friendly Agreement to Combine the Two Organizations and Create a Leader in Healthcare Innovation
    4. Roche Completes Tender Offer for Genentech
    5. Agendia Supports Genentechs Citizens Petition Urging FDA to Hold In-Vitro Diagnostic Tests to One Set of Scientific and Regulatory Standards
    6. MRC Technology Enters Into an Exclusive License Agreement With Genentech
    7. PDL BioPharma Provides Third Quarter 2010 Revenue Guidance of Approximately $86 Million and Update to its Correspondence With Genentech
    8. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
    9. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
    10. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
    11. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/22/2014)... solution of rod-shaped metal nanoparticles in water with ultrasound ... drill bits. Why? No one yet knows exactly. But ... (NIST) have clocked their speedand it,s fast. At up ... times faster than any nanoscale object submerged in liquid ... has opened up the possibility that they could be ...
    (Date:7/22/2014)... DALLAS , July 22, 2014   ... replacement therapy using natural, bio-identical hormone pellets, today ... , MD to the company.   Dr. Rouzier is ... training physician.      Dr. Rouzier was ... at UCLA and is a board certified emergency ...
    (Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and ... and other markets, announced today that it has closed ... private investors led by Novit L.P., an investment arm ... involved the signing of a Securities Purchase Agreement under ... at a price per share of $1.00, resulting in ...
    (Date:7/22/2014)... Rice Lake, Wisconsin (PRWEB) July 22, 2014 ... will be in attendance at the 2014 NCSL ... Florida. Booth #423 will feature CONDEC pressure ... balance style weights, and the new, customized sets, ... years ago to promote cooperative efforts in solving ...
    Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
    ... Dr. Kyong S. Choe, of Kwangju, South Korea, has been ... outstanding contributions and achievements in the field of healthcare. ... Dr. Choe is currently practicing with Feldman, Fitzgerald ... periodontics and prosthodontics targeting implants and full prosthetic reconstruction.  He ...
    ... on Tel Aviv Stock Exchange. - Common Stock to List on both Tel ... the Ticker Symbol PLX -,- Company Anticipates Joining TASE,s TA-75, TA-100, Tel-Tech, Tel-Tech ... to Dual List on Tel Aviv Stock Exchange -- CARMIEL, Israel, Aug. 30 ... ...
    ... August 30, 2010 ... if ... var shortURL = ""; BitlyCB.alertResponse = ... to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
    Cached Biology Technology:Dr. Kyong S. Choe Recognized by Strathmore's Who's Who Worldwide Publication 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 3Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 4Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 5Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 6Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 7Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9
    (Date:7/22/2014)... chances are you are), help may be on the ... developed a vaccine that can combat dust-mite allergies by ... the nano-sized vaccine package lowered lung inflammation by 83 ... the paper, published in the AAPS (American ... reason why it works, the researchers contend, is because ...
    (Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
    (Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
    Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
    ... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
    ... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
    ... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
    Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
    HSV-2 gD (0191)...
    ...
    ...
    RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
    Biology Products: